Table 3.
Associations between NUGs and CMSS in patients of the MDACC study and Harvard study
| Genotype | MDACC | Harvard | |||||||
|---|---|---|---|---|---|---|---|---|---|
|
|
|
||||||||
| All | Death (%) | HR (95% CI)b | Pb | All | Death (%) | HR (95% CI)c | Pc | ||
| NUGa | |||||||||
| 0 | 46 | 2 (4.3) | 1.00 | 19 | 0 (0) |
|
1.00d | ||
| 1 | 204 | 10 (4.9) | 1.34 (0.29–6.26) | 7.07E-01 | 102 | 7 (6.9) | |||
| 2 | 358 | 39 (10.9) | 2.84 (0.68–11.85) | 1.51E-01 | 164 | 17 (10.4) | 1.96 (0.81–4.74) | 1.34E-01 | |
| 3 | 214 | 34 (15.9) | 5.09 (1.22–21.28) | 2.59E-02 | 104 | 16 (15.4) | 2.96 (1.21–7.20) | 1.71E-02 | |
| 4 | 36 | 10 (27.8) | 9.96 (2.17–45.75) | 3.12E-03 | 20 | 8 (40.0) | 10.49 (3.76–29.28) | 7.25E-06 | |
| Trend test | 1.47E-07 | 3.12E-05 | |||||||
| 0–2 | 608 | 51 (8.4) | 1.00 | 285 | 24 (8.4) | 1.00 | |||
| 3–4 | 250 | 44 (17.6) | 2.62 (1.73–3.96) | 5.39E-06 | 124 | 24 (19.4) | 2.52 (1.43–4.45) | 1.43E-03 | |
Abbreviations: NUGs, number of unfavorable genotypes; CMSS, cutaneous melanoma-specific survival; MDACC, The University of Texas M.D. Anderson Cancer Center; HR, hazards ratio; CI, confidence interval.
a
Unfavorable genotypes were rs10916352 CC+CG, rs3851552 CC+TC, rs72635537 TT+CT, and rs7826362 TT+AT.
b
Adjusted for age, gender, Breslow thickness, stage, ulceration, and mitotic rate.
c
Adjusted for age and gender.
d
Combined the individuals with NUGs of 0 and 1 as reference.